What does “Prezcobix FDA review 505(b)(2)” mean?
“Prezcobix” is the brand name for a fixed-dose combination of darunavir (an HIV protease inhibitor) plus cobicistat (a pharmacokinetic booster). An FDA “505(b)(2)” application is a type of drug approval pathway that allows the sponsor to rely in part on existing data (for example, from previously approved products) while still submitting some new clinical or nonclinical information.
The “FDA review” part of the phrase usually refers to publicly available documents tied to FDA’s assessment (application review materials, labeling, approval history, and sometimes review memos) for that specific regulatory submission.
What review documents are typically available for a 505(b)(2) submission?
For an FDA drug action that used the 505(b)(2) pathway, public materials you may see (depending on what FDA posted for that particular product and time period) include things like:
- FDA approval letter and action history
- Labeling (Highlights of Prescribing Information and full label)
- Medical review / pharmacology review summaries (availability varies)
- Approvability and other internal review documents may exist publicly, but access is not guaranteed for every submission
If you’re trying to locate “the FDA review” specifically, the most reliable approach is to start from the product’s FDA submission page and then open any attached review documentation that FDA made public.
How was Prezcobix approved, and why does 505(b)(2) matter?
The practical reason people look for “Prezcobix 505(b)(2)” is to understand what FDA relied on versus what the sponsor had to generate for the new product submission. Under 505(b)(2), FDA can incorporate prior findings about one or more components or related formulations, then evaluate the specific combination product (Prezcobix) based on the data the sponsor submitted for that product.
This can affect what you’ll find in the review package—e.g., less new evidence than a full “505(b)(1)” pathway, but still a complete assessment of the combination’s safety, dosing, and labeling.
Where to find the exact Prezcobix 505(b)(2) review?
To pull the exact “Prezcobix FDA review 505(b)(2)” documents, you typically need one of the following identifiers:
- NDA number for Prezcobix
- the application/supplement number associated with the submission you mean
- the FDA approval date (or the review docket entry, if any)
Then you can search the FDA database(s) tied to that NDA/application for the uploaded review documents.
What if you meant a later supplement (not the original Prezcobix approval)?
“FDA review 505(b)(2)” searches sometimes turn up supplements that change labeling, indications, dosing, or formulations (and those supplements can also be handled through 505(b)(2)-type frameworks depending on what is being changed). If you’re looking for the wrong date/version, you might see a different labeling period or different review files.
If you share the NDA number, I can point you to the right review
If you tell me either:
- the NDA number (or application number), or
- the FDA approval year/date you’re interested in,
I can help you identify which specific FDA review materials correspond to that 505(b)(2) submission for Prezcobix and what each document is meant to cover.
Sources
No sources were provided in your message, so I can’t cite FDA documents directly yet.